PARDES BIOSCIENCES, INC.

Pardes Biosciences, Inc. (Nasdaq: PRDS) is a clinical-stage biopharmaceutical company that went public in 2022 following an S-1/A amendment filing in January of that year. The company operates in the antiviral therapeutics segment of the life sciences sector, with its development efforts centered on oral small-molecule treatments targeting SARS-CoV-2 and other coronaviruses. Pardes does not have a SPAC sponsor, having accessed public markets through a traditional initial public offering. As of its last disclosed status, the company had been evaluating strategic alternatives following a competitive shift in the COVID-19 antiviral landscape. Investors and analysts seeking full filing history, ownership data, and pipeline disclosures for PRDS can access comprehensive coverage by signing up for SpacDesk.